Video library

Burden and pathogenesis of gout

Rheumatologist Michael Spiegel discusses the burden and pathogenesis of gout and the importance of individualized treatment.

Gout and comorbidities

Rheumatologist Michael Spiegel discusses the prevalence of major comorbidities in patients with gout and the impacts they have on treatment.

The role of colchicine in gout-flare prophylaxis

Rheumatologist Michael Spiegel discusses the role of colchicine in the treatment of gout, and the benefits of a liquid colchicine to optimize dose adjustments.

GLOPERBA: The first and only liquid colchicine^1,2

Rheumatologist Michael Spiegel discusses GLOPERBA, the liquid colchicine that simplifies precise dose adjustments and eliminates the need for splitting pills or skipping doses.

Overview of gout and GLOPERBA

Rheumatologist Michael Spiegel discusses all of the topics listed above in one comprehensive video.

Interdisciplinary panelist discussion on gout

Alvin F. Wells, MD, PhD, Eugene E. Wright Jr, MD, and Iris Zink, MSN, RN, ANP-BC, RN-BC, discuss the role of GLOPERBA during an interdisciplinary forum on individualized gout-flare prophylaxis.

Explore why GLOPERBA may be right for your patients

Find out about the important role of colchicine in prophylaxis

Important Safety Information for GLOPERBA^® (colchicine)

Colchicine 0.6 mg oral solution is contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given GLOPERBA.
Fatal overdoses have been reported with colchicine in adults and children. Keep GLOPERBA out of the reach of children.
Blood dyscrasias, such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia, have been reported with colchicine used in therapeutic doses.
Monitor for toxicity and, if present, consider lowering the dose, temporary interruption, or discontinuation of colchicine.
Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider lowering the dose, temporary interruption, or discontinuation of GLOPERBA.
The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

GLOPERBA 0.6 mg oral solution is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of GLOPERBA for acute treatment of gout flares during prophylaxis has not been studied.

GLOPERBA is not an analgesic medication and should not be used to treat pain from other causes.

You are encouraged to report negative side effects of prescription drugs to the FDA. To report suspected adverse reactions, visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information for GLOPERBA.

References: 1. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm. Current through December 2020. Accessed December 7, 2020. 2. GLOPERBA [package insert]. Alpharetta, GA: Avion Pharmaceuticals, LLC; 2019.